HomeCompareBTTAY vs EPRT

BTTAY vs EPRT: Dividend Comparison 2026

BTTAY yields 0.06% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $29.1K in total portfolio value
10 years
BTTAY
BTTAY
● Live price
0.06%
Share price
$24.23
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.3K
Annual income
$8,071.06
Full BTTAY calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — BTTAY vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTTAYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTTAY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTTAY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTTAY
Annual income on $10K today (after 15% tax)
$4.85/yr
After 10yr DRIP, annual income (after tax)
$6,860.40/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $4,334.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTTAY + EPRT for your $10,000?

BTTAY: 50%EPRT: 50%
100% EPRT50/50100% BTTAY
Portfolio after 10yr
$49.8K
Annual income
$10,620.96/yr
Blended yield
21.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BTTAY
No analyst data
Altman Z
1.8
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTTAY buys
0
EPRT buys
0
No recent congressional trades found for BTTAY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTTAYEPRT
Forward yield0.06%3.97%
Annual dividend / share$0.01$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%29%
Portfolio after 10y$35.3K$64.3K
Annual income after 10y$8,071.06$13,170.85
Total dividends collected$14.7K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BTTAY vs EPRT ($10,000, DRIP)

YearBTTAY PortfolioBTTAY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,711$11.40$11,212$512.01$501.00EPRT
2$11,484$22.83$12,689$692.09$1.2KEPRT
3$12,334$45.75$14,521$944.30$2.2KEPRT
4$13,289$91.83$16,841$1,302.88$3.6KEPRT
5$14,404$184.94$19,841$1,821.64$5.4KEPRT
6$15,787$374.70$23,818$2,587.47$8.0KEPRT
7$17,660$767.61$29,230$3,744.65$11.6KEPRT
8$20,501$1,604.98$36,816$5,540.38$16.3KEPRT
9$25,419$3,482.62$47,806$8,413.17$22.4KEPRT
10$35,269$8,071.06$64,324$13,170.85$29.1KEPRT

BTTAY vs EPRT: Complete Analysis 2026

BTTAYStock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Full BTTAY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BTTAY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTTAY vs SCHDBTTAY vs JEPIBTTAY vs OBTTAY vs KOBTTAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.